Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Decrease in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 42,000 shares, a drop of 89.4% from the October 31st total of 396,100 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 263,800 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Trading of Xilio Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of XLO. XTX Topco Ltd acquired a new position in shares of Xilio Therapeutics during the 2nd quarter worth $32,000. Renaissance Technologies LLC raised its stake in Xilio Therapeutics by 18.3% during the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock worth $280,000 after acquiring an additional 45,554 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after acquiring an additional 155,337 shares during the last quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Price Performance

Shares of NASDAQ:XLO traded up $0.01 on Wednesday, hitting $1.00. The company had a trading volume of 11,941 shares, compared to its average volume of 518,390. The stock has a 50 day moving average price of $0.92 and a 200 day moving average price of $0.94. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $1.93.

Wall Street Analysts Forecast Growth

Separately, Raymond James reduced their price target on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.